Latest Breaking News On - எலும்பியல் மீளுருவாக்கம் தொழில்நுட்பங்கள் இன்க் - Page 1 : comparemela.com

Company confident of providing requested information over the coming weeks Phase I/II clinical trial preparation activities to continue in preparation of anticipated IND approval. MONTREAL, June 4, 2021 /PRNewswire/ - Ortho or the Company ), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration ( FDA ) related to its Investigational New Drug (IND) application to begin a phase I/II clinical trial for ORTHO-R, its drug/biologic combination product candidate used as an adjunct to standard of care surgery in rotator cuff tear repair.

Claude leducOrtho regenerative technologies incDrug administrationRegenerative technologiesInvestigational new drugChief executive officerPlatelet rich plasmaBone marrow aspirate concentrateLooking statementsOrtho regenerative technologies inc stock exchangePress releaseCtivities ortif ca68752f1036கிளாட் லிடக்எலும்பியல் மீளுருவாக்கம் தொழில்நுட்பங்கள் இன்க்மீளுருவாக்கம் தொழில்நுட்பங்கள்தலைமை நிர்வாகி அதிகாரி